EGFR基因突变与肺腺癌新分类及临床病理特征的关系

被引:11
作者
贺锐 [1 ]
李建民 [2 ]
王跃华 [2 ]
高宁 [2 ]
机构
[1] 山西医科大学基础医学院
[2] 山西省肿瘤医院病理科
关键词
肺肿瘤; 腺癌; 新分类; 表皮生长因子受体; 基因突变;
D O I
10.13315/j.cnki.cjcep.2013.12.028
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
目的根据2011年国际肺癌研究协会、美国胸科学会和欧洲呼吸学会发布的肺腺癌国际多学科分类(简称新分类)标准,评估新分类法与EGFR突变之间的相关性。方法收集2010~2012年肺腺癌标本共292例,其中145例手术标本分别使用新分类和WHO(2004版)分类(简称WHO分类)进行组织分型,并用基因直接测序法对所有标本EGFR基因外显子18~21(E18~21)进行检测。结果有123例(42.1%)标本发生EGFR突变,新分类法中各组织学亚型之间突变情况不同(P=0.006),EGFR突变多发于贴壁、微乳头为主的肺腺癌,含贴壁结构、乳头结构和微乳头结构亚型的肺腺癌,少见于腺泡、实体为主伴黏蛋白型(实体为主)及含浸润变异结构的肺腺癌。按WHO分类各亚型之间EGFR突变无明显差异。结论新分类表现出与分子诊断的相关性,其提倡的按5%增量的半定量方式将>5%的各组织学亚型及其所占百分比全面计入诊断(5%增量半定量法)的综合分类法应该被推广。
引用
收藏
页码:1323 / 1328
页数:6
相关论文
共 10 条
[1]   肺腺癌IASLC/ATS/ERS国际多学科分类解读 [J].
朱雄增 ;
张杰 .
临床与实验病理学杂志, 2012, (03) :241-243
[2]  
Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients[J] . Akihiko Yoshizawa,Shinji Sumiyoshi,Makoto Sonobe,Masashi Kobayashi,Masakazu Fujimoto,Fumi Kawakami,Tatsuaki Tsuruyama,William D. Travis,Hiroshi Date,Hironori Haga.Journal of Thoracic Oncology . 2013 (1)
[3]   International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma [J].
Travis, William D. ;
Brambilla, Elisabeth ;
Noguchi, Masayuki ;
Nicholson, Andrew G. ;
Geisinger, Kim R. ;
Yatabe, Yasushi ;
Beer, David G. ;
Powell, Charles A. ;
Riely, Gregory J. ;
Van Schil, Paul E. ;
Garg, Kavita ;
Austin, John H. M. ;
Asamura, Hisao ;
Rusch, Valerie W. ;
Hirsch, Fred R. ;
Scagliotti, Giorgio ;
Mitsudomi, Tetsuya ;
Huber, Rudolf M. ;
Ishikawa, Yuichi ;
Jett, James ;
Sanchez-Cespedes, Montserrat ;
Sculier, Jean-Paul ;
Takahashi, Takashi ;
Tsuboi, Masahiro ;
Vansteenkiste, Johan ;
Wistuba, Ignacio ;
Yang, Pan-Chyr ;
Aberle, Denise ;
Brambilla, Christian ;
Flieder, Douglas ;
Franklin, Wilbur ;
Gazdar, Adi ;
Gould, Michael ;
Hasleton, Philip ;
Henderson, Douglas ;
Johnson, Bruce ;
Johnson, David ;
Kerr, Keith ;
Kuriyama, Keiko ;
Lee, Jin Soo ;
Miller, Vincent A. ;
Petersen, Iver ;
Roggli, Victor ;
Rosell, Rafael ;
Saijo, Nagahiro ;
Thunnissen, Erik ;
Tsao, Ming ;
Yankelewitz, David .
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (02) :244-285
[4]  
Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy[J] . Adi F. Gazdar.Cancer and Metastasis Reviews . 2010 (1)
[5]  
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway[J] . Kim-Son H. Nguyen,Susumu Kobayashi,Daniel B. Costa.Clinical Lung Cancer . 2009 (4)
[6]   The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain [J].
Red Brewer, Monica ;
Choi, Sung Hee ;
Alvarado, Diego ;
Moravcevic, Katarina ;
Pozzi, Ambra ;
Lemmon, Mark A. ;
Carpenter, Graham .
MOLECULAR CELL, 2009, 34 (06) :641-651
[7]  
ErbBs in lung cancer[J] . Sreenath V. Sharma,Jeffrey Settleman.Experimental Cell Research . 2008 (4)
[8]  
Correlation between morphology and EGFR mutations in lung adenocarcinomas[J] . Hironori Ninomiya,Miyako Hiramatsu,Kentaro Inamura,Kimie Nomura,Michiyo Okui,Tatsu Miyoshi,Sakae Okumura,Yukitoshi Satoh,Ken Nakagawa,Makoto Nishio,Takeshi Horai,Satoshi Miyata,Eiju Tsuchiya,Masashi Fukayama,Yuichi Ishikawa.Lung Cancer . 2008 (2)
[9]  
Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis[J] . Noriko Motoi,Janos Szoke,Gregory J. Riely,Venkatraman E. Seshan,Mark G. Kris,Valerie W. Rusch,William L. Gerald,William D. Travis.The American Journal of Surgical Pathology . 2008 (6)
[10]   EGFR mutation is specific for terminal respiratory unit type adenocarcinoma [J].
Yatabe, Y ;
Kosaka, T ;
Takahashi, T ;
Mitsudomi, T .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (05) :633-639